Opportunity Information: Apply for PAR 10 095
Apply for PAR 10 095
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jan 26, 2010 and posted on Jan 26, 2010.
- Applicants must submit their applications by Mar 22, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public housing authorities/Indian housing authorities Small businesses Independent school districts Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education City or township governments Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02)" (Funding Opportunity Number PAR-10-095) is a National Institutes of Health initiative led by the National Institute on Drug Abuse (NIDA) that focuses on building a pipeline of strong candidates for a larger, high-impact medication development award. Its central goal is to encourage researchers to submit an X02 pre-application, which functions as the initial screening step for those who want to compete for the full NIDA Translational Avant Garde Award. The program is aimed at basic and clinical scientists who have the creativity, experience, and momentum to move promising discoveries out of the laboratory or clinic and into real-world treatments, specifically medications for addiction-related conditions.
The scientific and public health emphasis is clearly on translational medication development for substance use disorders tied to major drugs of abuse. NIDA highlights tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioids as priority areas. The broader intent is to speed up progress toward treatments that are not only innovative, but also demonstrably safe and effective, addressing urgent and persistent gaps in addiction care. In practical terms, this means NIDA is looking for investigators who can connect mechanistic or clinical insights to concrete product-development trajectories, bridging the space between discovery research and candidate therapeutics.
This particular announcement uses the X02 mechanism, which is important because it does not provide research funding by itself. Instead, it serves as a formal pre-application pathway for the associated, main funding opportunity (RFA-DA-10-013). Under PAR-10-095, no awards are made and no money is distributed; the value lies in being considered for progression to the full Translational Avant Garde Award competition. NIDA’s financial commitment is tied to the companion FOA rather than this pre-application: the agency anticipated investing roughly $2 million per year for five years to support approximately 2 to 3 awards under the main mechanism. The implication for applicants is that the X02 submission is essentially the gateway step to a substantial, multi-year funding opportunity designed for high-potential, high-responsibility translational leaders.
Eligibility is broad and includes a wide range of organizational types across the nonprofit, academic, governmental, and private sectors. Eligible applicants listed include public and private institutions of higher education; nonprofit organizations both with and without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and multiple levels of government such as state, county, city or township, special district governments, and independent school districts. It also explicitly includes tribal entities and affiliated organizations (including federally recognized tribal governments and other tribal organizations), public housing authorities/Indian housing authorities, and U.S. territories or possessions. The eligibility notes further expand the pool to include Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, and eligible federal agencies. The announcement also specifies that there is no cost sharing or matching requirement, which removes a common barrier for some applicants.
Administratively, the opportunity falls under the NIH, within the Health funding activity area, and is associated with CFDA number 93.279 (Drug Abuse and Addiction Research Programs). Key dates indicate it was posted and created on January 26, 2010, with an original and current closing date of March 22, 2010, and an archive date of April 22, 2010. The opportunity is categorized as discretionary and uses a grant funding instrument, though again, the X02 here is purely a pre-application step rather than a direct award vehicle. For applicants seeking official details, NIH provided an announcement link through the NIH Grants Guide, and support contacts were routed through the NIH Office of Extramural Research (OER) webmaster for access or technical linking issues.
Overall, PAR-10-095 is best understood as a structured entry point into a prestigious translational medication development program at NIDA. It signals NIDA’s intent to identify and cultivate investigators capable of moving beyond incremental research advances and toward deliverable addiction medications, while using the X02 pre-application as the first filter before inviting or enabling full applications under the better-funded companion FOA.
Frequently Asked Questions (FAQs)
What is the official title of this grant opportunity?
The opportunity is titled "Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PAR-10-095.
Which federal agency is offering this opportunity?
This is a National Institutes of Health (NIH) initiative led by the National Institute on Drug Abuse (NIDA).
What is the purpose of PAR-10-095?
The purpose is to encourage researchers to submit an X02 pre-application that serves as an initial screening step for those who want to compete for the full NIDA Translational Avant Garde Award for medication development.
Is PAR-10-095 a direct funding opportunity?
No. This announcement uses the X02 mechanism and does not provide research funding by itself. Under PAR-10-095, no awards are made and no money is distributed; it is a formal pre-application pathway for the associated main funding opportunity.
What is the value of submitting an X02 pre-application under this announcement?
The value is in being considered for progression to the full Translational Avant Garde Award competition. The X02 submission is described as the gateway step into the larger, high-impact medication development award process.
What is the companion (main) funding opportunity associated with this X02 pre-application?
The companion main funding opportunity is RFA-DA-10-013.
What kind of research focus is NIDA looking for in this program?
The emphasis is on translational medication development for substance use disorders, with the aim of moving promising discoveries from the laboratory or clinic into real-world addiction treatments.
Which substances or drug areas are highlighted as priorities?
NIDA highlights tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioids as priority areas.
Who is the program intended for?
The program is aimed at basic and clinical scientists who have the creativity, experience, and momentum to translate mechanistic or clinical insights into concrete medication development trajectories for addiction-related conditions.
What does "translational" mean in the context of this announcement?
Based on the description provided, "translational" refers to bridging the space between discovery research and candidate therapeutics, with a focus on product-development pathways that can lead to safe and effective medications for substance use disorders.
What types of organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and multiple levels of government organizations.
Are government entities eligible applicants?
Yes. Eligible applicants include state, county, city or township governments, special district governments, independent school districts, and eligible federal agencies.
Are tribal entities eligible?
Yes. The eligibility list explicitly includes tribal entities and affiliated organizations, including federally recognized tribal governments and other tribal organizations.
Are U.S. territories eligible?
Yes. U.S. territories or possessions are included in the eligible applicant types.
Are public housing authorities eligible to apply?
Yes. Public housing authorities/Indian housing authorities are explicitly listed as eligible.
Are faith-based or community-based organizations eligible?
Yes. The eligibility notes explicitly include faith-based or community-based organizations.
Are minority-serving institutions included in eligibility?
Yes. The eligibility notes specifically mention Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Is there a cost sharing or matching requirement?
No. The announcement specifies that there is no cost sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The CFDA number is 93.279 (Drug Abuse and Addiction Research Programs).
What is the funding instrument type listed for this opportunity?
The opportunity is listed under a grant funding instrument, although this X02 announcement itself is a pre-application step and does not make awards.
What is the funding activity area associated with this opportunity?
The opportunity falls under the Health funding activity area.
What are the key dates for this opportunity?
It was posted/created on January 26, 2010. The original and current closing date is March 22, 2010. The archive date is April 22, 2010.
Is this opportunity still open based on the dates provided?
No. The closing date is listed as March 22, 2010, and the archive date is April 22, 2010, indicating it is no longer active.
How much funding is associated with the overall program?
NIDA's financial commitment is tied to the companion FOA (RFA-DA-10-013), not the X02 pre-application. NIDA anticipated investing roughly $2 million per year for five years to support approximately 2 to 3 awards under the main mechanism.
How many awards were anticipated under the main mechanism?
Approximately 2 to 3 awards were anticipated under the main mechanism, according to the information provided.
Where can applicants find the official announcement details?
NIH provided an announcement link through the NIH Grants Guide for official details.
Who should be contacted for access or technical linking issues related to the announcement?
Support contacts for access or technical linking issues were routed through the NIH Office of Extramural Research (OER) webmaster.
How should applicants interpret PAR-10-095 overall?
PAR-10-095 is best understood as a structured entry point into a prestigious NIDA translational medication development program, using the X02 pre-application as the first filter before competing for the better-funded companion opportunity.
Browse more opportunities from the same category: Education Health
Next opportunity: 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1)
Previous opportunity: Cooperative Ecosystem Studies Unit, Piedmont South Atlantic CESU
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 095
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 095) also looked into and applied for these:
| Funding Opportunity |
|---|
| 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 10 013 Funding Number: RFA DA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for Substance Related Disorders (R01) Apply for RFA DA 10 018 Funding Number: RFA DA 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) Apply for RFA DA 10 019 Funding Number: RFA DA 10 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21) Apply for RFA NR 10 002 Funding Number: RFA NR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Apply for RFA HL 11 002 Funding Number: RFA HL 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Clinical Trials in Drug Abuse (Collaborative R01) Apply for PAR 10 099 Funding Number: PAR 10 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 10 126 Funding Number: PAR 10 126 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) Apply for RFA NR 10 005 Funding Number: RFA NR 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (R01) Apply for RFA NR 10 004 Funding Number: RFA NR 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 10 131 Funding Number: PA 10 131 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 10 129 Funding Number: PA 10 129 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 10 130 Funding Number: PA 10 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 095", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.